Skip to content

Devyser webinar

Devyser RHD*: High performance without complexity 

Date and time:  April 29, 2025 | 4pm CET | 10am ET

Why attend this webinar? 

Get the complete picture of why Devyser RHD sets a new standard for fetal RHD screening.

  • Simple by design 
    Discover how Devyser RHD’s unique single-exon assay simplifies analysis and reduces inconclusive results. With few steps and a streamlined workflow, it’s easier than ever to implement reliable fetal RHD genotyping into your lab routine. 
  • Performance in clinical use 
    Backed by large-scale validation studies, Devyser RHD delivers 99.9% sensitivity and 99.95% specificity, helping avoid unnecessary prophylaxis and ensure confident clinical decisions as early as week 10 of pregnancy. 
  • Trusted in practice 
    With over 100,000 pregnancies tested, 12 years of product expertise, and CE-IVDR, Risk Class D, certification, Devyser RHD is a proven, trusted solution in national screening programs and high-throughput settings. 

Don't miss this opportunity to explore how Devyser RHD shapes non-invasive RHD genotyping. 

Feel free to submit your questions beforehand if you want them addressed during the webinar.

 

*Disclaimer: Devyser products are distributed worldwide. Not all intended uses and applications mentioned here are available in every country. Please consult your local sales representative for details.